PURPOSE: This AUA Guideline focuses on evaluation/counseling and management of adult patients with clinically localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS AND METHODS: Systematic review utilized research from the Agency for Healthcare Research and Quality and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A/B/C (Strong/Moderate/Conditional Recommendations, respectively) with additional statements presented as Clinical Principles or Expert Opinions. RESULTS: Great progress has been made since the previous guidelines on management of localized renal masses were released (2009). The current guidelines provide updated, evidence-based recommendations regarding evaluation/counseling of patients with clinically localized renal masses, including the evolving role of renal mass biopsy. Given great variability of clinical, oncologic and functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Management options (partial nephrectomy/radical nephrectomy/thermal ablation/active surveillance) are reviewed including recent data about comparative effectiveness and potential morbidities. Oncologic issues are prioritized while recognizing that functional outcomes are of great importance for survivorship for most patients with localized kidney cancer. A more restricted role for radical nephrectomy is recommended following well-defined selection criteria. Priority for partial nephrectomy is recommended for clinical T1a lesions, along with selective use of thermal ablation, particularly for tumors ≤3.0 cm. Important considerations for shared decision-making about active surveillance are explicitly defined. CONCLUSIONS: Several factors should be considered during counseling/management of patients with clinically localized renal masses, including general health/comorbidities, oncologic potential of the mass, pertinent functional issues and relative efficacy/potential morbidities of various management strategies.
PURPOSE: This AUA Guideline focuses on evaluation/counseling and management of adult patients with clinically localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS AND METHODS: Systematic review utilized research from the Agency for Healthcare Research and Quality and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A/B/C (Strong/Moderate/Conditional Recommendations, respectively) with additional statements presented as Clinical Principles or Expert Opinions. RESULTS: Great progress has been made since the previous guidelines on management of localized renal masses were released (2009). The current guidelines provide updated, evidence-based recommendations regarding evaluation/counseling of patients with clinically localized renal masses, including the evolving role of renal mass biopsy. Given great variability of clinical, oncologic and functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Management options (partial nephrectomy/radical nephrectomy/thermal ablation/active surveillance) are reviewed including recent data about comparative effectiveness and potential morbidities. Oncologic issues are prioritized while recognizing that functional outcomes are of great importance for survivorship for most patients with localized kidney cancer. A more restricted role for radical nephrectomy is recommended following well-defined selection criteria. Priority for partial nephrectomy is recommended for clinical T1a lesions, along with selective use of thermal ablation, particularly for tumors ≤3.0 cm. Important considerations for shared decision-making about active surveillance are explicitly defined. CONCLUSIONS: Several factors should be considered during counseling/management of patients with clinically localized renal masses, including general health/comorbidities, oncologic potential of the mass, pertinent functional issues and relative efficacy/potential morbidities of various management strategies.
Authors: Emily A Knott; John F Swietlik; Katherine C Longo; Rao F Watson; Chelsey M Green; E Jason Abel; Meghan G Lubner; J Louis Hinshaw; Amanda R Smolock; Zhen Xu; Fred T Lee; Timothy J Ziemlewicz Journal: J Vasc Interv Radiol Date: 2019-05-23 Impact factor: 3.464
Authors: Anas M Saad; Mohamed M Gad; Muneer J Al-Husseini; Inas A Ruhban; Mohamad Bassam Sonbol; Thai H Ho Journal: Clin Genitourin Cancer Date: 2018-10-11 Impact factor: 2.872
Authors: Maria C Mir; Nicola Pavan; Umberto Capitanio; Alessandro Antonelli; Ithaar Derweesh; Oscar Rodriguez-Faba; Estefania Linares; Toshio Takagi; Koon H Rha; Christian Fiori; Tobias Maurer; Chao Zang; Alexandre Mottrie; Paolo Umari; Jean-Alexandre Long; Gaelle Fiard; Cosimo De Nunzio; Andrea Tubaro; Andrew T Tracey; Matteo Ferro; Ottavio De Cobelli; Salvatore Micali; Luigi Bevilacqua; João Torres; Luigi Schips; Roberto Castellucci; Ryan Dobbs; Giuseppe Quarto; Pierluigi Bove; Antonio Celia; Bernardino De Concilio; Carlo Trombetta; Tommaso Silvestri; Alessandro Larcher; Francesco Montorsi; Carlotta Palumbo; Maria Furlan; Ahmet Bindayi; Zachary Hamilton; Alberto Breda; Joan Palou; Alfredo Aguilera; Kazunari Tanabe; Ali Raheem; Thomas Amiel; Bo Yang; Estevão Lima; Simone Crivellaro; Sisto Perdona; Caterina Gregorio; Giulia Barbati; Francesco Porpiglia; Riccardo Autorino Journal: World J Urol Date: 2019-04-01 Impact factor: 4.226
Authors: Yafu Yin; Scott P Campbell; Mark C Markowski; Philip M Pierorazio; Martin G Pomper; Mohamad E Allaf; Steven P Rowe; Michael A Gorin Journal: Mol Imaging Biol Date: 2019-06 Impact factor: 3.488
Authors: Brett A Johnson; Sandy Kim; Ryan L Steinberg; Alberto Diaz de Leon; Ivan Pedrosa; Jeffrey A Cadeddu Journal: Urol Oncol Date: 2019-09-17 Impact factor: 3.498